Podcast appearances and mentions of Mark Robson

Mark Robson joins me this week to explore the world of grilling and smoking food. We discuss the excitement of grilling season, advancements in pellet grill technology, and share our personal grilling journeys since 2016. Mark highlights his Yoder pellet grill, Rectech, and Komodo Joe Big Joe, focusing on their unique cooking capabilities. Our conversation touches on smoked meats, jerky-making tips, and the importance of grill maintenance. We also reflect on the communal joy of grilling and speculate on future technologies, including AI integration. This episode is packed with insights for grill enthusiasts looking to enhance their skills. Thanks for

Mark Robson joins me this week to explore the world of grilling and smoking food. We discuss the excitement of grilling season, advancements in pellet grill technology, and share our personal grilling journeys since 2016. Mark highlights his Yoder pellet grill, Rectech, and Komodo Joe Big Joe, focusing on their unique cooking capabilities. Our conversation touches on smoked meats, jerky-making tips, and the importance of grill maintenance. We also reflect on the communal joy of grilling and speculate on future technologies, including AI integration. This episode is packed with insights for grill enthusiasts looking to enhance their skills. Thanks for

Mark Robson joins me this week to explore the world of grilling and smoking food. We discuss the excitement of grilling season, advancements in pellet grill technology, and share our personal grilling journeys since 2016. Mark highlights his Yoder pellet grill, Rectech, and Komodo Joe Big Joe, focusing on their unique cooking capabilities. Our conversation touches on smoked meats, jerky-making tips, and the importance of grill maintenance. We also reflect on the communal joy of grilling and speculate on future technologies, including AI integration. This episode is packed with insights for grill enthusiasts looking to enhance their skills. Thanks for

Lost Command es una película bélica estadounidense dirigida por Mark Robson, protagonizada por Anthony Quinn, Alain Delon, George Segal, Michèle Morgan y Claudia Cardinale. La trama se desarrolla durante la Guerra de Independencia de Argelia (1954-1962), un conflicto que sumió a Francia en una profunda crisis política y social. Tras la derrota francesa en Indochina, el ejército, liderado por personajes como el coronel Raspeguy (Quinn), busca reafirmar su autoridad en Argelia. Sin embargo, la brutal represión militar y las divisiones internas en Francia —entre quienes exigían mano dura y quienes rechazaban la violencia— agudizaron el conflicto. La película explora estos dilemas morales, la lealtad de las tropas y el impacto de la guerra en ambos bandos. Te lo cuentan Juan Pastrana y Esaú Rodríguez. Y recuerda que puedes encontrar el blog 📽️ Todo sobre mi Cine Bélico en https://todosobremicinebelico.blogspot.com/ Casus Belli Podcast pertenece a 🏭 Factoría Casus Belli. Casus Belli Podcast forma parte de 📀 Ivoox Originals. 📚 Zeppelin Books (Digital) y 📚 DCA Editor (Físico) http://zeppelinbooks.com son sellos editoriales de la 🏭 Factoría Casus Belli. Estamos en: 🆕 WhatsApp https://bit.ly/CasusBelliWhatsApp 👉 X/Twitter https://twitter.com/CasusBelliPod 👉 Facebook https://www.facebook.com/CasusBelliPodcast 👉 Instagram estamos https://www.instagram.com/casusbellipodcast 👉 Telegram Canal https://t.me/casusbellipodcast 👉 Telegram Grupo de Chat https://t.me/casusbellipod 📺 YouTube https://bit.ly/casusbelliyoutube 👉 TikTok https://www.tiktok.com/@casusbelli10 👉 https://podcastcasusbelli.com 👨💻Nuestro chat del canal es https://t.me/casusbellipod ⚛️ El logotipo de Casus Belli Podcasdt y el resto de la Factoría Casus Belli están diseñados por Publicidad Fabián publicidadfabian@yahoo.es 🎵 La música incluida en el programa es Ready for the war de Marc Corominas Pujadó bajo licencia CC. https://creativecommons.org/licenses/by-nd/3.0/ El resto de música es bajo licencia privada de Epidemic Music, Jamendo Music o SGAE SGAE RRDD/4/1074/1012 de Ivoox. 🎭Las opiniones expresadas en este programa de pódcast, son de exclusiva responsabilidad de quienes las trasmiten. Que cada palo aguante su vela. 📧¿Queréis contarnos algo? También puedes escribirnos a casus.belli.pod@gmail.com ¿Quieres anunciarte en este podcast, patrocinar un episodio o una serie? Hazlo a través de 👉 https://www.advoices.com/casus-belli-podcast-historia Si te ha gustado, y crees que nos lo merecemos, nos sirve mucho que nos des un like, ya que nos da mucha visibilidad. Muchas gracias por escucharnos, y hasta la próxima. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

El demonio está entre nosotros... o, como poco, sus acólitos. Al menos así es en el mundo que pintan las tres películas de las que hablamos en este podcast. La afable pareja de vejetes que vive en el piso de al lado o una reunión social de gente educada y elegante pueden ser el disfraz bajo el que se ocultan miembros de una secta satánica. «La séptima víctima» (The Seventh Victim, Mark Robson, 1943), «La novia del diablo» (The Devil Rides Out, Terence Fisher, 1968) y «La semilla del diablo» (Rosemary's Baby, Roman Polanski, 1968) coinciden en mostrar una trama de conspiraciones para extender por el mundo la sombra del Maligno que se destapa bajo una apariencia de normalidad social. De paso, cada una de ellas constituye una lección cinematográfica, ya sea en el sugerir sin mostrar absolutamente nada («La séptima víctima»), en el fascinar aun mostrándolo todo («La novia del diablo») o en el hacernos reconstruir una turbia historia que corre paralela e invisible a la de la protagonista («La semilla del diablo»). Participan en este humilde aquelarre Miguel Muñoz Garnica, Érica Couto y José Luis Forte.

Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes. CME information and select publications here.

Featuring perspectives from Dr Kevin S Hughes and Dr Mark Robson, including the following topics: Introduction (0:00) Optimal Approach to Genetic Testing for Patients with Localized Breast Cancer (BC) — Dr Hughes (10:22) Available Data with and Practical Application of PARP Inhibition as Adjuvant Therapy for Patients with BC — Dr Robson (38:06) CME information and select publications

Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes. CME information and select publications here.

Welcome to Episode 95 of The Modelgeeks Podcast!  In this episode we were very fortunate in this episode to sit down and speak with Mark Robson of Kōtare Scale ModelsAs always, we've all been busy at the bench…and at our keyboards! We'll talk about cool new items coming our way, and what we've worn out the ol' credit card on as well.We would like to thank all you listeners out there for the continued support you have given the show. As we roll through Winter and on towards springtime, I hope that your bench is active and you're completing those subjects that you plan to share with the modeling public out at a show or contest. Get to the bench and build something!Share your work with us and the rest of the scale modeling community through our web page, or through our Facebook community page. We love seeing other people's work. Who knows who you may inspire someone through your latest masterpiece!Modelgeeks web page:Model Geeks PodcastFacebook community:The ModelGeeks Model Shackand of course you can email us at:contact@modelgeekspodcast.com Mentioned in the Episode:Masters of the Air Behind the Scenes, a Facebook page taking a behind the scenes look at what went in to making the MOTA. Lots of great reference photos of aircraft support equipment, vehicles, uniforms, etc.Masters Of The Air Behind The Scenes  We also want to thank each of our sponsors for their support. We are very lucky to have their support. When you have the time, pay a visit to their web sites, and have a look at their fine products. Sponsors:Furball Aero-DesignTamiya USADetail & ScaleSprueBrothersLionHeart HobbyBases By BillHypersonic ModelsMatters Of ScaleIf you're a wicked ModelGeek go check out the following links!IPMS USA Events PageButch O'Hare Modeling ClubThe Interesting Modeling CompanyWe are very fortunate to be able to join the scale modeling podcast community and are in the company of several other really GREAT podcasts. Hopefully, someday we'll earn our wings and be able to keep up with those guys!  Please check them all out at Scale Model Podcasts. Blogs:The Kit BoxSprue Pie with FretsModel Airplane MakerSupport the showSupport the showModel Geeks PodcastSupport the showModel Geeks Podcast

Jaume Segalés y su equipo hablan de cine clásico, de FITUR y de la obra Los gigantes de la montaña. Hoy en Km0, tras repasar la actualidad informativa y deportiva, profundizamos en los siguientes asuntos: "Los Gigantes de la Montaña" Esta semana se ha estrenado en el teatro Fernán Gómez-Centro Cultural de la Villa (Plaza de Colón, n.º 4) "Los Gigantes de la Montaña". Se trata de la última obra que escribió el dramaturgo italiano (Premio Nobel de Literatura) Luigi Pirandello y que fue estrenada por primera vez en en 1937. Podemos disfrutar de la versión que nos trae la compañía AlmaViva Teatro en en Sala Jardiel Poncela hasta el 23 de febrero, a las 20:30 de martes a sábados y los domingos a las 19:30. Está considerado uno de los textos más complejos de Pirandello. y una de sus piezas clave. Nos brinda una serie de alegorías que exploran la relación entre el arte, la sociedad y la imaginación. Está dividida en tres actos, pero el tercero quedó inconcluso. Cuenta la historia de una compañía de teatro que llega a la misteriosa posada conocida como La Scalogna (que significa "mala suerte") de camino a una montaña habitada por gigantes, donde los actores están convocados para interpretar una de sus obras en la celebración de una boda. Entrevistamos al director de AlmaViva Teatro y de la obra, Cesar Barló. Japón en FITUR Entrevistamos a Hajime Kishi, manager en España de la Organización Oficial de Turismo de Japón (JNTO) para conocer la propuesta y los detalles de la participación nipona en la 45ª edición de la Feria Internacional de Turismo (FITUR) que organiza y acoge IFEMA. Sección de cine clásico Es sesión continua Antolín de la Torre hoy nos habla sobre El premio (The Prize). Película estadounidense de 1963 dirigida por Mark Robson, con Paul Newman, Elke Sommer y Edward G. Robinson en los papeles principales y basada en el best seller "The Prize", de Irving Wallace. Fue galardonada con el premio Globo de Oro de 1964 a la actriz Elke Sommer como nueva estrella del año. Andrew Craig (Paul Newman) llega a Estocolmo para recibir el Premio Nobel de Literatura. Es un hombre que parece más interesado en las mujeres y el alcohol que en escribir. Es recibido por su hermosa acompañante asignada, Inger Lisa Andersson (Elke Sommer), y se aloja en el Grand Hôtel, residencia oficial de los laureados. Allí conoce a otro premiado, el Dr. Max Stratman (Edward G. Robinson), físico y refugiado político que está acompañado por su sobrina Emily (Diane Baker). El encuentro se desarrolla con cordialidad y quedan de acuerdo en reunirse al día siguiente.

The Leopard Man (1943), The Seventh Victim (1943), Isle of the Dead (1945) Back in episode 23, we covered producer Val Lewton and three of his films. While Lewton only produced about a dozen films—and only a handful of them horror—his work made a huge impact on the genre. That's why we've decided to discuss three more of his films, hoping to inspire other fans to seek out not only the ones we've covered but his other titles as well. With the help of a talented group of craftsmen—including directors Jacques Tourneur and Mark Robson, screenwriter Ardel Wray, and a skilled cast of actors he worked with repeatedly—Lewton created films that stood apart. They weren't just different from what he was hired to produce; they defied the expectations of most horror fans at the time. His films had style, compelling stories, and uniquely well-developed characters. They're a testament to how effective something as simple as a walk down the street can be when crafted by the right people. Films mentioned in this episode: The Body Snatcher (1945), Cat People (1942), The Curse the Cat People (1944), Curse of the Demon (1957), The Day After (1983), Isle of the Dead (1945), I Walked with a Zombie (1943), The Leopard Man (1943), Old Dark House (1932), The Seventh Victim (1943)

Agents Scott and Cam barrel through snowy Europe on a train with Lee Marvin and Robert Shaw while tackling the 1979 spy action movie Avalanche Express.  Directed by Mark Robson. Starring Lee Marvin, Robert Shaw, Linda Evans, Maximilian Schell, Joe Namath, Horst Buchholz and Mike Connors. Become a SpyHards Patron and gain access to top secret "Agents in the Field" bonus episodes, movie commentaries and more! Purchase the latest exclusive SpyHards merch at Redbubble. Social media: @spyhards View the NOC List and the Disavowed List at Letterboxd.com/spyhards Podcast artwork by Hannah Hughes. Theme music by Doug Astley.

This week Harrison will review "The 7th Victim" (1943) starring Tom Conway and directed by Mark Robson ⁠#the7thvictim⁠ ⁠#tomconway⁠ ⁠#markrobson⁠⁠#reelyoldmovies⁠ Join my Discord!:   / discord   Social Media Links: https://linktr.ee/reelyoldmovies

Subscriber-only episodeJackie and Greg turn up the camp for Mark Robson's VALLEY OF THE DOLLS from 1967. Topics of discussion include the film's subtlety (or lack thereof), its wild production history, cult status, and how it's stuck between the Old and New Hollywood.The monthly S'mores series is an offshoot from our main series, where Jackie and Greg explore films from the fringes of cinema, encompassing underground, experimental, cult, camp, genre, horror, and B-movies. S'mores episodes are unlocked by becoming either a Patron or Friend of the Show (see below). These episodes are released on the last Tuesday of each month.Check us out on Instagram: instagram.com/sceneandheardpodCheck us out at our official website: sceneandheardpod.comJP Instagram/X (Twitter): jacpostajGK Instagram: gkleinschmidtGraphic Design: Molly PintoMusic: Andrew CoxEditing: Greg KleinschmidtGet in touch at hello@sceneandheardpod.comSupport the show on Patreon: patreon.com/SceneandHeardPodorSubscribe just to get access to our bonus episodes: buzzsprout.com/1905508/subscribe

Mark Robson is my guest this week. We discussed various topics, including extreme weather patterns in Canada, grilling and cast iron cooking techniques, barbecue techniques and ingredients, and culinary creativity and experimentation. Mark shared his experiences and insights on using high-quality charcoal, proper airflow, and experimentation to find the right cooking methods for individual preferences. Mark emphasized the importance of trying new things and experimenting with different techniques to improve one’s skills in these areas. Thanks for listening! Full show notes, transcriptions (available on request), audio and video at http://theAverageGuy.tv/hgg616 Join Jim Collison / @jcollison for show #616 of Home

Mark Robson is my guest this week. We discussed various topics, including extreme weather patterns in Canada, grilling and cast iron cooking techniques, barbecue techniques and ingredients, and culinary creativity and experimentation. Mark shared his experiences and insights on using high-quality charcoal, proper airflow, and experimentation to find the right cooking methods for individual preferences. Mark emphasized the importance of trying new things and experimenting with different techniques to improve one's skills in these areas. Thanks for listening! Full show notes, transcriptions (available on request), audio and video at http://theAverageGuy.tv/hgg616 Join Jim Collison / @jcollison for show #616 of Home

Mark Robson is my guest this week. We discussed various topics, including extreme weather patterns in Canada, grilling and cast iron cooking techniques, barbecue techniques and ingredients, and culinary creativity and experimentation. Mark shared his experiences and insights on using high-quality charcoal, proper airflow, and experimentation to find the right cooking methods for individual preferences. Mark emphasized the importance of trying new things and experimenting with different techniques to improve one's skills in these areas. Thanks for listening! Full show notes, transcriptions (available on request), audio and video at http://theAverageGuy.tv/hgg616 Join Jim Collison / @jcollison for show #616 of Home

We would like to welcome our new sponsors to Jake's Place Songs n TailsBoreal Pet Foods -  https://borealpetfood.comPure Wet Wipes -  https://www.purewetwipes.com/ Song's Played in this episode: Publishing infoTia McGraff / Fawn Ti Publishing - SOCANTommy Parham/ MandiTY Music - ASCAP Little Corner Of The World: Day In My Shoes album Beautiful Universe: Michael Patterson , Garry Benns, Mark Robson, David Burnip PPL PublishingLife Carries On ( ft. Dave Taggart ): Michael Patterson , PPL PublishingLindisfarne  ( ft. Jen Stevens): Michael Patterson , PPL PublishingAll songs by Michael Patterson played by permission.Michael Pattersonhttps://www.youtube.com/@kickstarter154https://www.youtube.com/@skyrushofficialmusicchannelhttps://www.facebook.com/SkyRushUK Niagara SPCA Humane Society   https://niagaraspca.com/ Acoustic Guitar Instrumental Background Music for Videos I No Copyright Music Jake's Place Songs'n'Tails logo design by Ryan Szucs https://www.facebook.com/szucs.ryanIntro Song: Abigail - from the Break These Chains CDOutro Song: Radical Road- from the Diversity CDwww.tiamcgraff.comJake's Place Song n Tails merchandise is available athttps://tiamcgraff.com/lake-country-storehttps://www.youtube.com/channel/UCIenjKbCobp2jChW2SoCyog Jake's Place Songs'n'Tails logo design by Ryan Szucs https://www.facebook.com/szucs.ryanIntro Song: Abigail - from the Break These Chains CDOutro Song: Radical Road- from the Diversity CDwww.tiamcgraff.comJake's Place Song n Tails merchandise is available athttps://tiamcgraff.com/lake-country-storehttps://www.youtube.com/channel/UCIenjKbCobp2jChW2SoCyog

This week we have a whopping big episode for you: Part 2 of our look at Samuel Goldwyn Productions, dealing with the 1940s; and, in our Fear and Moviegoing in Toronto segment, brief discussions of three Powell and Pressburgers, kicking off TIFF's May retrospective. For this episode we watched The Little Foxes (directed by William Wyler), The Pride of the Yankees (directed by Sam Wood), The Best Years of Our Lives (Wyler again), and My Foolish Heart (directed by Mark Robson). From scheming capitalists to heroic baseball stars to casting a critical eye on post-WWII America to a grown-up soap opera that defies the Production Code, we consider the legacy of the innovative independent producer who not only hired intellectuals but let them do their thing.  Time Codes: 0h 00m 30s:      THE LITTLE FOXES (1942) [dir. William Wyler] 0h 26m 57s:      THE PRIDE OF THE YANKEES (1942) [dir. Sam Wood] 0h 39m 40s:      THE BEST YEARS OF OUR LIVES (1946) [dir. William Wyler] 1h 01m 00s:      MY FOOLISH HEART (1949) [dir. Mark Robson] 1h 19m 38s:      Fear and Moviegoing in Toronto: The Red Shoes (1948), The Life and Death of Colonel Blimp  (1943) and I Know Where I'm Going  (1945) – all by Michael Powell and Emeric Pressburger +++ * Listen to our guest episode on The Criterion Project – a discussion of Late Spring * Marvel at our meticulously ridiculous Complete Viewing Schedule for the 2020s * Intro Song: “Sunday” by Jean Goldkette Orchestra with the Keller Sisters (courtesy of The Internet Archive) * Read Elise's piece on Gangs of New York – “Making America Strange Again” * Check out Dave's Robert Benchley blog – an attempt to annotate and reflect upon as many of the master humorist's 2000+ pieces as he can locate – Benchley Data: A Wayward Annotation Project!  Follow us on Twitter at @therebuggy Write to us at therebuggy@gmail.com We now have a Discord server - just drop us a line if you'd like to join! 

Auckland-based Kotare Models has been awarded a prestigious "Model of the year 2024" medal at the recent Nuremburg Toy Fair.  Mark Robson from Kotare Models speaks to Emile Donovan.

'Barbie,' from director Greta Gerwig, is a fantasy comedy starring Margot Robbie and Ryan Gosling based on the iconic doll from Mattel. It is nominated for eight Academy Awards: Best Picture, Best Supporting Actor - Ryan Gosling, Best Supporting Actress - America Ferrara, Best Adapted Screenplay, Best Costume Design, Best Production Design and two nominations for Best Original Song: I'm Just Ken by Mark Robson and Andrew Wyatt, and What Was I Made For by Billy Eilish and Finneas O'Connell.

We review Earthquake (1978) on movie podcast The Collector's Cut. Earthquake is directed by Mark Robson and stars Charlton Heston, Ava Gardner, George Kennedy, Lorne Greene, Richard Roundtree patreon: https://www.patreon.com/mildfuzztv twitter: https://twitter.com/ScreamsMidnight email: mftvquestions@gmail.com Audio version: https://the-collectors-cut.pinecast.co/

Val Lewton, producteur poète et visionnaire, a révolutionné le cinéma d'horreur en produisant seulement 11 films.

First-team coach and former Hammers player Mark Robson joins the pod to discuss his route into coaching, first impressions of Lucas Paqueta and whether we'll see any January transfer activity. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Isabelle Bedrosian and Dr. Mark Robson discuss the new guideline from ASCO and SSO on germline testing in patients with breast cancer. They discuss the framework for which patients should be offered BRCA1/2 testing, and what additional moderate- and high-penetrance genes may be considered for inclusion in germline testing. They highlight key aspects of personal and family history, recommendations surrounding counseling for genetic testing, and the impact for patients and their families. They close the conversation with a discussion of gaps in the research. Read the full guideline, Germline Testing in Patients with Breast Cancer: ASCO-SSO Guideline TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest disclosures in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.23.02225 Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts, delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.  My name is Brittany Harvey, and today I'm interviewing Dr. Isabelle Bedrosian from the University of Texas MD Anderson and Dr. Mark Robson from Memorial Sloan Kettering Cancer Center, co-chairs on “Germline Testing in Patients with Breast Cancer: American Society of Clinical Oncology – Society of Surgical Oncology Guideline.”  Thank you for being here, Dr. Bedrosian and Dr. Robson. Dr. Mark Robson: My pleasure. Dr. Isabelle Bedrosian: Thank you, Brittany. Brittany Harvey: Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Bedrosian and Dr. Robson, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes.  So then, to jump into the content of this particular guideline, Dr. Bedrosian, could you give us a general overview of both the scope and the purpose of this guideline? Dr. Isabelle Bedrosian: Yeah, sure. So, in the last decade or so, the whole area of clinical cancer genetics has become incredibly complicated, driven, I think, predominantly by the development of extended gene testing. And in the midst of this complexity, our goal here was to try to give providers a framework through which they can think about the application of germline testing within their patient population. And really, this framework was to help them think through how testing can best be applied to patients that were both newly diagnosed with breast cancer or had a history of breast cancer, and also to help them think through the scope of that testing as well, be it BRCA testing or testing in a more extended fashion that may help inform longer-term decisions such as risk management. Brittany Harvey: Absolutely. We appreciate your efforts to provide recommendations in this framework in this complicated space.  So then, I'd like to review the key recommendations of this guideline developed by the expert panel. So first, Dr. Robson, who should be offered BRCA1/2 testing? Dr. Mark Robson: Thank you. I think this is perhaps one of the most important things that comes out of the guideline is that we, and the group, are now recommending that anyone who is either newly diagnosed with breast cancer at or before the age of 65, or if they're over 65 and have suggestive personal or family history criteria, or alternatively, if they are eligible for PARP inhibitor therapy, that they all be offered BRCA1 or BRCA2 testing. And the same would hold for women who had a personal history of breast cancer but were not currently under active treatment if their diagnosis had been made at or before 65 or older than that, with certain criteria then they should be offered testing. This is a much simpler way to look at things than the rather complicated existing criteria, which are perhaps a bit both difficult to remember and unfortunately inadequately sensitive in a setting where there is such critical, both therapeutic and risk management implications to the identification of a BRCA mutation. Dr. Isabelle Bedrosian: Yeah, I would just also add there's one other, albeit a much smaller group of women for whom BRCA testing could be considered, and those are women who develop a second primary breast cancer. That's another group that I think we can think about offering BRCA1/2 testing to. Brittany Harvey: Understood. I appreciate you both reviewing those recommendations for BRCA1/2 testing.  So, Dr. Bedrosian, which additional genes does the panel recommend including in germline testing? Dr. Isabelle Bedrosian: Yeah. So, in this area, outside of BRCA genes, Brittany, I think the panel didn't make any definitive recommendations or any specific genes that should be tested for. I think the panel felt that the decision to test for additional high penetrance genes and also for some moderate penetrance genes should be guided by the specifics of the individual case, whether the identification of germline mutations makes sense in the context of the patient's personal history and family history. So, in other words, is there a worrisome pattern in the family that might warrant more in-depth testing beyond BRCA, and also considerations around the implications of those test results. Would it change the management for the patient themselves? Either in the treatment of the index malignancy, which, in the case of most of these non-BRCA genes, there really is not changes to the management of the breast cancer that would be offered based on the finding of non-BRCA germline mutations. But potentially, the finding of a non-BRCA germline mutation in a breast cancer patient might help better understand risks of second malignancies that would then be addressed. And certainly for families as well of the patients, identifying those that are carriers could offer opportunities for risk assessment, risk mitigation. Dr. Mark Robson: I totally agree with Dr. Bedrosian. One thing I think it's important to understand is that most commercial testing done in the United States now does involve panels of genes. And the group certainly did not intend to suggest that that practice not continue. So, I think if somebody has a history of breast cancer, I think the panel felt that it would at least be reasonable to test for breast cancer susceptibility genes. However, this issue of do you test for all of the high penetrance genes when the family history doesn't suggest it, was certainly something we left open and we did not want to imply that it was obligatory to test for a large number or large panel of genes that weren't related to the patient's personal and family history. So, in other words, didn't want to imply that it was obligatory to do an extremely large panel just as a target of opportunity, if you will. Dr. Isabelle Bedrosian: I think really a key part of these guidelines was that we wanted to afford the oncologist flexibility. It's very difficult beyond BRCA to be prescriptive. There are so many considerations about testing, and those considerations will be applied differently in every patient context. So, we really wanted to let providers know that while they have to think about these other genes, and oftentimes there'll be good reason to do these other genes as part of the overall germline testing, again, that it's not obligatory to do so. It's not a fixed set that needs to be tested for. And really, the understanding of the patient's personal history, family history, therapeutic goals, and risk assessment goals should be used to determine kind of the ultimate scope of the testing. Brittany Harvey: It sounds like these decisions will be individualized, based on patient characteristics and with working between both patients and their clinicians. So that leads into my next question. But, Dr. Robson, how should patients with breast cancer considering genetic testing be counseled? Dr. Mark Robson: With this recognition and emphasis on the therapeutic implications for patients with breast cancer, both surgical and potentially systemic using PARP inhibitors, the approach has gradually moved away from the concept of testing for personal utility, in other words, just wanting to know, and more towards the idea of this being a clinically useful test that's to some extent necessary for the appropriate management of a fair number of patients. And so the counseling is usually- the pre-test counseling is perhaps more educational than we have used in the past, rather than this extensive discussion of whether or not somebody wants to know. Obviously, it's always the patient's ultimate decision whether or not to be tested, and we have to give them the same elements of education that we would have given back in the day. But it can be delivered in a more didactic type of context rather than necessarily the back and forth that takes place with formal genetic counseling.  Now, for patients who have complicated or extensive family histories or who have histories that may suggest predispositions other than those for breast cancer, the type of thing that Dr. Bedrosian was talking about earlier, they could certainly benefit, again, from a more formal evaluation by a provider experienced in cancer genetics to help select what the scope of the testing should be, for instance, and also to help interpret those results. And certainly anybody who had a pathogenic variant or a likely pathogenic variant identified should be considered for meeting with somebody who's experienced in clinical cancer genetics both to interpret and also to help with family expansion when appropriate.  Brittany Harvey: Excellent. Thank you for reviewing those recommendations from the expert panel. So, Dr. Robson just touched on this a little bit, but Dr. Bedrosian, how will these guideline recommendations affect patients with breast cancer and their families? Dr. Isabelle Bedrosian: Yeah, so from a patient perspective, I think there are two ways that these recommendations can impact care. For those women that are identified as germline carriers, specifically with BRCA, it will open the door for receipt of PARP inhibitors, which are currently recommended for patients that are high-risk primary cancer or those with metastatic disease. The other ways that patients will be affected by a germline testing is really in this idea of second cancer risks. Some of these germline mutations are well established to carry risks of either second primary breast cancer or non-breast malignancies. And understanding those risks will allow the patients and their providers to create management strategies, be they surgical or with more intensified screening that will help them mitigate the effects of that germline-driven risk.  And I think similarly for the families of patients, the ones the proband has identified, I think that family now has a very real opportunity to better understand their cancer risks and again be able to more effectively manage those risks through either surgical or non-surgical means. And it would really underscore the family component of this. I think oftentimes oncologists are very much focused on the patient and admittedly so that is the person that has the most immediate needs. But I think there's a real opportunity to extend efforts at prevention and early detection by identifying the at-risk family members and allowing them the opportunity to access care that mitigates their cancer risks and hopefully will improve survival outcomes in so doing. So, I think the opportunities for families here to understand risks of germline testing is a really important one to underscore from these recommendations. Dr. Mark Robson: Just to expand a little bit on what Dr. Bedrosian was saying, I think this is a very important place for collaboration between the oncology community and the clinical cancer genetics providers because the oncologist is pretty occupied taking care of all of their cancer patients, and the approach to people who are unaffected is a little bit different. People who are unaffected perhaps do need a little bit more pretest counseling to understand the pros and cons of choosing to be tested for the familial mutation. And certainly that idea of family expansion is something that's well known to clinical cancer genetics providers and that's really very much something that they can help the primary oncologists do. Brittany Harvey: Absolutely, these recommendations have impacts beyond just the individual patient, but also for their families as well.  So then, finally, Dr. Robson, what are the outstanding questions regarding germline testing in breast cancer? Dr. Mark Robson: Oh, there are so many. Where should I start? I think over the years we've become, as a community, pretty comfortable managing individuals who have BRCA1 or BRCA2 mutations. There are certainly some questions left, but there's a lot of familiarity with that. I think the challenges expand into these what we call moderate penetrance genes and how to guide people with alterations in those genes. Because except for PALB2, which is relatively uncommon, many of the other genes don't really have the same implications for therapy because it's not clear that they confer PARP sensitivity. It's not at all clear that they have high risks of contralateral breast cancer. And even in the unaffected setting, we know that there's a wide distribution of risk for people who carry these alterations. And some individuals with these alterations probably are not at increased risk at all because they have protective factors. So the management of breast cancer susceptibility genes beyond BRCA1 and BRCA2 is still very much in evolution. They can't be handled exactly the same way as a woman with a BRCA carrier.   And then, of course, this issue of how much should we test and what do we do with some of the alterations that we find, if you will, out of context, what are the implications for that and what's the most appropriate management? Those still remain very much open questions. So I think there's still plenty of work to do. Dr. Isabelle Bedrosian: Yeah, I agree. I think one of the enormous challenges has been the disconnect between how rapidly our technology has advanced and can sequence alterations, and our ability to really understand the biologic and clinical implications, which really is a time-dependent issue. We need to see over time how patients do for us to understand the implications of some of these germline findings. So that disconnect is a very difficult one to bridge, particularly, I think, for surgical oncologists because they are oftentimes referred patients who don't have a cancer history, necessarily, or have a distant history, and really the concern is “I'm at risk and I would like to reduce my risk.” And it becomes very difficult to counsel patients as to the benefits of risk reduction when we don't have such a great handle on the degree to which they are actually at risk. So that really is a significant gap, I think, for surgeons in particular to have to contend with. Brittany Harvey: Definitely. We'll look forward to answering some of those questions as we learn more and get more data to address those gaps.  So I want to thank you both so much for your work to develop this framework for genetic testing in breast cancer, and thank you so much for your time today, Dr. Robson and Dr. Bedrosian. Dr. Isabelle Bedrosian: Thank you, Brittany.  Dr. Mark Robson: Thank you for having us. Brittany Harvey: Thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.

POP ART 111 says SOAPY SALES: Join me and my guest Sam Homrig (attorney by day, murder mystery host by night as well as co-host of “The Cabot Cove Confab Podcast”, “The Columbo Confab Podcast”, and “The Best Picture Podcast”)   “We were just playing a game called Photography. You turn off the lights and see what develops.” Lies, deceit, adultery, murder, teen sex, drugs, abortion by proxy, incest by proxy, illegitimate children, coded gay characters…Sounds like it's time for Episode 111 of Pop Art, the podcast where we find the pop culture in art and the art in pop culture. It's the podcast where my guest chooses a movie from popular culture, and I'll select a film from the more art/classic/indie/foreign side of cinema with a connection to it.   For this episode, I am happy to welcome as my guest, Sean Homrig, who has chosen as his film Ang Lee's dissection of suburban life in 1970s Connecticut, The Ice Storm, while I have chosen Mark Robson's dissection of small town New England life in the 1940s, Peyton Place, both soap opera looks at small towns.     And in this episode, we answer such questions as: What scandal made Peyton Place one of the top grossing movies of that year? Why are soap operas so appealing? What rating from the Catholic Church was given to Peyton Place? What are the anachronisms and historical inaccuracies of both films? What Cannes award did The Ice Storm receive? What changes from the book did they make in bringing Peyton Place to the screen? What is inaccurate about the death in The Ice Story? How many Oscar acting nominations did Peyton Place receive?   Be sure and check out Sean's various podcasts, “The Cabot Cove Confab Podcast”, “The Columbo Confab Podcast”, and “The Best Picture Podcast”.   Check out my blog at https://howardcasner.wordpress.com/   My books, More Rantings and Ravings of a Screenplay Reader, The Starving Artists and Other Stories and The Five Corporations and One True Religion can be found at https://www.amazon.com/s?k=howard+casner&ref=nb_sb_noss   Be sure to like, follow or comment on my podcast. I'd love to know what you think. And check out the other episodes. --- Support this podcast: https://podcasters.spotify.com/pod/show/howard-casner/support

Jack Mason, host of The Perfume Nationalist podcast joins me to talk about Jacqueline Susann's 1966 novel of showbiz, sex, and substance abuse, Valley of the Dolls, as well as the 1967 film adaptation directed by Mark Robson and starring Sharon Tate, Patty Duke, and Susan Hayward, and also the 1970 film Beyond the Valley of the Dolls, directed by Russ Meyer and written by film critic Roger Ebert!Subscribe to The Perfume Nationalist here: https://www.patreon.com/perfumenationalist

Today I welcome Robbo to the show where we talk about developing self confidence in the younger generation and into adulthood. Disclaimer: these podcast episodes are sharing my personal experiences, stories from mentors and guests around self esteem, confidence, personal growth and mental health. For any serious mental health concerns and advice please consult with a professional such as a doctor, therapist or what seems appropriate.

For our Halloween 2023 episode, we take you on a tour of Peyton Place—the 1956 novel by Grace Metalious, 1957 Fox movie starring Lana Turner, and the mid-late-60s TV series starring Dorothy Malone and Mia Farrow (among many others) that reinvented television. We discuss the strange journey of Metalious's scabrous and scathing vision from satire to soap opera, in the course of which the story of shack-dweller Selena Cross's violation by her stepfather becomes the story of lower-middle-class Betty Anderson's resentful ambition, while ostensible protagonist Allison MacKenzie goes from being a bit of a jerk to being a nightmare of willfulness. But which versions of the story influenced David Lynch the most? We give our surmises.    Time Codes: 0h 00m 45s:    Peyton Place by Grace Metalious 0h 42 m 52s:   PEYTON PLACE (1957) [dir. Mark Robson] 1h 02m 26s:    PEYTON PLACE – TV SERIES (1964 to 1969) +++ * Listen to our guest episode on The Criterion Project – a discussion of Late Spring * Marvel at our meticulously ridiculous Complete Viewing Schedule for the 2020s * Intro Song: “Sunday” by Jean Goldkette Orchestra with the Keller Sisters (courtesy of The Internet Archive) * Read Elise's piece on Gangs of New York – “Making America Strange Again” * Check out Dave's Robert Benchley blog – an attempt to annotate and reflect upon as many of the master humorist's 2000+ pieces as he can locate – Benchley Data: A Wayward Annotation Project!  Follow us on Twitter at @therebuggy Write to us at therebuggy@gmail.com We now have a Discord server - just drop us a line if you'd like to join! 

Bedazzle the cobwebs and yassify the cemetery: it's that time again, the third annual Overlapping Dialogue Spooktober Spooktacular! We dive into the Halloween spirit in with two black and white chillers from the 30s and 40s with Vampyr and Isle of the Dead. In addition to tangling with the undead, we get fat and happy with a Blue Plate Special bag of goodies, ranging from thoughts on the new Wes Anderson shorts adapting Roald Dahl on Netflix, predictions on what effects Swifties will have on theaters with the release of Taylor Swift: The Eras Tour, and puzzle our way through Rolling Stones Magazine's ranking of the "50 Worst Decisions in Movie History." It's a *scary* good episode that may or may not conclude with us chowing down on some General Mills monster cereal. But which one? You'll have to listen to the very end to find out. As always, please like, subscribe, rate, and review us on all of our channels, which include Apple Podcasts, Spotify, and YouTube! Contact us at huffmanbrothersproductions@gmail.com with your questions, comments, and requests.

For our RKO 1943 episode, we look at two films that exemplify the nascent RKO noir style: Richard Wallace's The Fallen Sparrow, starring John Garfield as a traumatized Spanish Civil War veteran hunted by Nazis and the Val Lewton production The Seventh Victim, starring Kim Hunter as a sheltered young woman who wants to find out about the sorrows of the world and does not want to be told to drink her milk. Featuring cinematography by Nicholas Musuraca and scores by Roy Webb, these films embrace opacity and ooze paranoia while presenting portraits of sophisticated New York milieus harbouring evil in their midst. And, keeping to the noir theme, in Fear and Moviegoing in Toronto we discuss a 30th anniversary screening of Brian De Palma's Carlito's Way, starring Al Pacino as a gangster who carries his doom around inside him.  Time Codes: 0h 00m 45s:      THE FALLEN SPARROW [(dir. Richard Wallace] 0h 29m 14s:      THE SEVENTH VICTIM [dir. Mark Robson] 1h 09m 06s:      FEAR & MOVIEGOING IN TORONTO – Brian De Palma's Carlito's Way (1993) at The Revue Cinema   Studio Film Capsules provided by The RKO Story by Richard B. Jewell & Vernon Harbin Additional studio information from: The Hollywood Story by Joel W. Finler                                     +++ * Marvel at our meticulously ridiculous Complete Viewing Schedule for the 2020s * Intro Song: “Sunday” by Jean Goldkette Orchestra with the Keller Sisters (courtesy of The Internet Archive) * Read Elise's latest film piece on Preston Sturges, Unfaithfully Yours, and the Narrative role of comedic scapegoating. * Check out Dave's new Robert Benchley blog – an attempt to annotate and reflect upon as many of the master humorist's 2000+ pieces as he can locate – Benchley Data: A Wayward Annotation Project!  Follow us on Twitter at @therebuggy Write to us at therebuggy@gmail.com   We now have a Discord server - just drop us a line if you'd like to join! 

“I don't have to live by stinking rules set for ordinary people.” Valley of the Dolls (1967) directed by Mark Robson and starring Barbara Parkins, Patty Duke, Sharon Tate, Lee Grant and Susan Hayward.   Next Time: Sylvia Scarlett (1935)

We continue last week's theme of Hollywood's attitude toward the Soviet Union as our Dorothy McGuire Acteurist Oeuvre-view episode takes us beyond not only the Popular Front era but just a shade beyond the heyday of McCarthyism. We also find that we spoke too soon about McGuire entering her mom-roles era, as in this episode's movies she embodies an unmarried professional woman with a liberal attitude toward sex and a shady political past in Trial (1955, directed by Mark Robson, based on the novel by Don Mankiewicz), as well as a Quaker minister (and wife and mother) whose family's pacifist views are put to the test in William Wyler's Friendly Persuasion (1956). McGuire brings her particular mixture of the soothing and the astringent to not very committed Communism and very committed pacifism, proving that her range encompasses both the ultra-worldly and the otherworldly.  Time Codes:  0h 0m 45s:      TRIAL (1955) [dir. Mark Robson] 0h 30m 25s:      FRIENDLY PERSUASION (1956) [dir. Wiliam Wyler]   +++ * Listen to our guest episode on The Criterion Project – a discussion of Late Spring * Marvel at our meticulously ridiculous Complete Viewing Schedule for the 2020s * Intro Song: “Sunday” by Jean Goldkette Orchestra with the Keller Sisters (courtesy of The Internet Archive) * Read Elise's piece on Gangs of New York – “Making America Strange Again” * Check out Dave's Robert Benchley blog – an attempt to annotate and reflect upon as many of the master humorist's 2000+ pieces as he can locate – Benchley Data: A Wayward Annotation Project!  Follow us on Twitter at @therebuggy Write to us at therebuggy@gmail.com We now have a Discord server - just drop us a line if you'd like to join! 

Our two Dorothy McGuire movies for this week are wildly different in tone: Samuel Goldwyn's I Want You (1951, directed by Mark Robson), about a family's reaction to the Korean War draft, and, for MGM, the Jamesian melodrama Invitation (1952, directed by Gottfried Reinhardt). Dave makes the case for I Want You as a complex leftist look at early Cold War America, and then we unpack the Jamesian tropes of Invitation, with its complicated flashback structure. And in our Fear and Moviegoing in Toronto segment, we share our first experience of the extraordinarily intense films of Hungarian auteur Márta Mészáros, discussing Nine Months (1976) and The Two of Them (1977). Time Codes: 0h 00m 45s:      I WANT YOU (1951) [dir. Mark Robson] 0h 37m 18s:      INVITATION (1952) [dir. Gottfried Reinhardt] 1h 07m 01s:      Fear and Moviegoing in Toronto – Nine Months (1976) and The Two of Them (1977) by Marta Meszaros   +++ * Listen to our guest episode on The Criterion Project – a discussion of Late Spring * Marvel at our meticulously ridiculous Complete Viewing Schedule for the 2020s * Intro Song: “Sunday” by Jean Goldkette Orchestra with the Keller Sisters (courtesy of The Internet Archive) * Read Elise's piece on Gangs of New York – “Making America Strange Again” * Check out Dave's Robert Benchley blog – an attempt to annotate and reflect upon as many of the master humorist's 2000+ pieces as he can locate – Benchley Data: A Wayward Annotation Project!  Follow us on Twitter at @therebuggy Write to us at therebuggy@gmail.com We now have a Discord server - just drop us a line if you'd like to join! 

Summer is a time for outdoor activities, and one of the best ways to enjoy the warm weather is to fire up the grill. For many, grilling is an essential part of the summer season, providing a delicious way to cook food and to bring friends and family together.

Summer is a time for outdoor activities, and one of the best ways to enjoy the warm weather is to fire up the grill. For many, grilling is an essential part of the summer season, providing a delicious way to cook food and to bring friends and family together.

Summer is a time for outdoor activities, and one of the best ways to enjoy the warm weather is to fire up the grill. For many, grilling is an essential part of the summer season, providing a delicious way to cook food and to bring friends and family together.

Jason Henderson of Castle of Horror podcast and Castle Bridge Media publishing joins Jim Towns for an in-depth discussion on RKO's The Seventh Victim, from 1943.Produced by Val Lewton and directed by first timer Mark Robson, the film stars a young Kim Hunter (Zira in Planet of the Apes), Lewton regular Tom Conway, Jean Brooks (The Leopard Man/The Invisible Man Returns) and  Hugh Beaumont ("Leave it to Beaver") in a dark tale of devil worship and mental derangement, evocatively photographed in stark black and white-a Lewton trademark.Content Warning: this episode contains discussions on suicide and mental illness.

'None shall sleep'. Jon Christos watched the Italia 90 World Cup with his Dad and says that the live performance of 'Nessun Dorma' by Pavarotti at the tournament was the only time he ever saw his Dad cry. Beatrice Venezia conducted 'Nessun Dorma' at the 'Puccini day' she created in Lucca in 2018. She also conducted Andrea Bocelli's performance of the aria at the Platinum Jubilee celebrations in June 2022. Pavarotti's daughter Cristina talks about the impact this aria had on her father's life and how his 1990 performance of 'Nessun Dorma' inspired many people to become interested in opera. Sir Bobby Robson's son Mark Robson was at Italia 90 and talks about the pride he felt seeing his Dad lining up with the England team for the semi-final against West Germany. It was also sung at Sir Bobby's memorial service in Durham Cathedral. Broadcaster and author Alexandra Wilson explains that the opera Turandot is the story of Prince Calaf who falls in love with the titular Princess. In 'Nessun Dorma' Calaf expresses his determination to win her hand, ending with that extraordinary refrain "Vincerò!" or "I will win". Paul Potts won 'Britain's Got Talent' in 2007 performing 'Nessun Dorma' and recalls singing it to over a million people at the Brandenburg Gate on New Year's Eve in 2010. When Italy locked down in March 2020, hairdresser Piero d'Angelico played 'Nessun Dorma' from a five-story window above Cambridge railway station to show solidarity with his home country and the Italian community in his adopted city. Voiceovers by Mike Ingham and Rebecca Braccialarghe. Producer: Toby Field for BBC Audio in Bristol Technical Producer: Michael Harrison Editor: Emma Harding

In this episode of SurgOnc Today®, Doreen Agnese, MD, from The Ohio State University Medical Center is joined by Toan Nguyen, MD, from Lakeland Regional Health and Mark Robson, MD, from Memorial Sloan Kettering Cancer Center. Realizing that genetic testing is being performed more frequently and by many different providers for patients both with and without breast cancer, they discuss the management of non-BRCA breast cancer susceptibility genes.

In this short episode, Dan and Tim talk about Mark Robson's The Harder They Fall (1956), know by its alternate title, Bogart's Last Movie.  But, as they both say, there's no reason to give this one a pity recommendation: it's solid stuff, a terrific look at a man who leaves his shell of cynicism to do the right thing, as we've seen in that other, lesser-known Bogart film.  The fix is in--give it a listen! Terrific bumper music:  Bluebird by E's Jammy Jams Creative Commons — Attribution 3.0 Unported— CC BY 3.0 https://creativecommons.org/licenses/... Music provided by FreeMusic109 https://youtube.com/FreeMusic109

Erin and Paul review two films about pleasant-looking small towns and suburbs that are actually hotbeds of lust and adultery: Todd Field's 2006 adaptation of Tom Perrotta's novel LITTLE CHILDREN and Mark Robson's 1957 adaptation of Grace Metalious' bestseller PEYTON PLACE. Plus: our quick takes on MOONAGE DAYDREAM, BONES AND ALL, SHE SAID, GLASS ONION, TAR, TERRIFIER 2, PIGGY, THE MENU, THE FABELMANS and ARMAGEDDON TIME.

On this episode of The Snub Club, our hosts discuss 1957's Peyton Place. Directed by Mark Robson and starring Lana Turner, Peyton Place was nominated for seven Academy Awards but lost all of them on awards night. In this episode, Danny, Sarah and Caleb discuss melodrama, Sam Rockwell, and who was skinny dipping in the lake last Labor Day.   The Snub Club is a biweekly podcast about cinema history where we discuss the film from every year's Academy Awards with the most nominations but no wins. Hosted by Danny Vincent, Sarah Knauf, and Caleb Bunn!   Follow us everywhere! Twitter: https://mobile.twitter.com/SnubClubPod Instagram: https://www.instagram.com/thesnubclubpodcast/ Facebook: https://m.facebook.com/permalink.php?story_fbid=108436691341808&id=108435618008582&substory_index=0   Theme music: That's All Right by Arthur Crudup

Cat People is a 1942 American horror film directed by Jacques Tourneur and produced for RKO by Val Lewton. The film tells the story of Irena Dubrovna, a newly married Serbian fashion illustrator obsessed with the idea that she is descended from an ancient tribe of Cat People who metamorphose into black panthers when aroused. When her husband begins to show interest in one of his coworkers, Irena begins to stalk her. The film stars Simone Simon as Irena, and features Kent Smith, Tom Conway, and Jane Randolph in supporting roles. 1000 stickers for $79 ONLY at this link www.riotstickers.com/frumess - the best in the business! JOIN THE PATREON FOR LESS THAN A $2 CUP OF COFFEE!! https://www.patreon.com/Frumess

Mark Robson is back with us this week for the annual BBQ and Grill show. We spend some time catching up with Mark and his grill set up at home. He has a few grills for sure. I also ask Mark about a grill/smoker that is on sale at Walmart and if it is right for me. It was a Pit Boss Austin XL 1000 Sq. In. Pellet Grill with Flame Broiler and Cooking Probe. I will have the link below. I did purchase the grill later that night. We also look at some yummy stuff Mark has cooked and

Mark Robson is back with us this week for the annual BBQ and Grill show. We spend some time catching up with Mark and his grill set up at home. He has a few grills for sure. I also ask Mark about a grill/smoker that is on sale at Walmart and if it is right for me. It was a Pit Boss Austin XL 1000 Sq. In. Pellet Grill with Flame Broiler and Cooking Probe. I will have the link below. I did purchase the grill later that night. We also look at some yummy stuff Mark has cooked and

In this episode, we discuss CHAMPION (1949; dir. Mark Robson).

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world's leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. Greg Guthrie: Hi, everyone. I'm Greg Guthrie, and I'm a member of the Cancer.Net content team, and I'll be your host for today's Cancer.Net podcast. Cancer.Net is the patient information website of ASCO, the American Society of Clinical Oncology. Today, we're going to be talking about the ASCO provisional clinical opinion, “Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer.” Our guests today are the co-chairs of the team that wrote these recommendations. Dr. Funda Meric-Bernstam from the University of Texas MD Anderson Cancer Center in Houston, Texas. Thank you for joining us today, Dr. Meric-Bernstam. Dr. Meric-Bernstam: Thank you for having us. Greg Guthrie: And our second guest today is Dr. Mark Robson from Memorial Sloan Kettering Cancer Center in New York City. Dr. Robson, thank you for joining us today, too. Dr. Robson: Thank you for having me. Greg Guthrie: So before we begin, I should mention that Dr. Meric-Bernstam does not have any relationships to disclose related to this podcast. Dr. Robson has led clinical trials in PARP inhibitors but has not received any personal compensation for this research. Full disclosures for this podcast can be found on Cancer.Net. So, Dr. Robson, let's begin by discussing what a provisional clinical opinion is and why they are important. Dr. Robson: So there are times when there are sea changes or incredibly important changes taking place in oncology practice. And sometimes these are clinical trial data, and sometimes they are more global. And this is a situation where it's one of those global challenges. And what ASCO does in situations like this is pull together a group of experts to provide guidance for the membership through a process of discussion and informal consensus rather than necessarily direct evaluation of clinical studies. And this is important because it allows the membership to benefit from these expert opinions. Greg Guthrie: Now, Dr. Meric-Bernstam, this provisional clinical opinion discusses somatic genomic testing in metastatic or advanced cancer. What is somatic genetic testing, and how is it used in cancer treatment? Dr. Meric-Bernstam: Oh, thank you. This is a really exciting time in the last decade. We have a lot more tools to understand cancer biology. And cancer is a genomically-driven phenomena, where there's alterations in the DNA, in the tumor, that confers the cancer cells a competitive growth and survival advantage. And only 10 years ago, we had the capability of doing this 1 gene at a time, to sequence a gene to see what is different, but now we have technologies where we can look at several hundred genes at a time. We are referring to these as multigene panels. And we're talking about genomic testing or somatic genomic testing. These are tests that look at several hundred genes, either looking at the tumor sequence alone or looking at the tumor sequence and comparing it to the normal sequence so we can see what has differed in the tumor that may give it a competitive advantage. We're doing this to be able to identify if there are genes that are altered that are therapeutically actionable. What we mean by that is, is there an alteration that we think confers the cancer cell an advantage for which we have a drug that either directly or indirectly we can use to help inhibit the cancer cell growth or preferably cause the cancer cell death? Greg Guthrie: Great. And so how is somatic testing different from germline testing? Dr. Robson: So somatic testing is testing the DNA or the nucleic acids, if you will, in the tumor itself, and germline testing is testing the DNA in normal tissue. And so the DNA in the normal tissue is what people are born with, and of course, most of the DNA in the tumor is the same as what people were born with. But there are specific changes that develop as the cancer arises, and it's those specific changes that are called somatic alterations. Dr. Meric-Bernstam: This is actually a really interesting point though because some tests report out germline alterations as well because only the tumor is sequenced, while some tests report the tumor, only subtracting what was in the germline. Thus, unless the germline result is specifically reported, a patient that has a known germline alteration may be surprised to see that it's not in the tumor report. And on the flip side, a tumor-only test may find a germline alteration, and thus it's important that physicians and patients are aware of that. That needs to be further pursued with the genetic testing. Greg Guthrie: Wow, just a wealth of information coming from this testing now. Sometimes I hear the term next-generation sequencing mentioned in regard to cancer. Does this provisional clinical opinion also touch on that? Dr. Meric-Bernstam: Yes. When we are referring to genomic testing panels or multigene panels, we are talking about the next-generation sequencing technology that has the ability now to use a small amount of tumor to be able to report out the sequence of several hundred genes. We have, of course, broader panels also coming, such as whole exome sequencing, whole genomic sequencing. Although, majority of our provisional clinical opinion is talking about the use of these in several hundred gene panels. Greg Guthrie: Amazing. Alright. Dr. Meric-Bernstam, so what should people with cancer and their loved ones know about this opinion? Dr. Meric-Bernstam: This has been a really complicated time because the introduction of next-generation sequencing made genomic testing available, but to be fair, not widely available initially. Only more recently is it more broadly available, and there's been some confusion about which patients with which diseases should get or can get genomic testing or would benefit from genomic testing. So we wanted to frame this by first highlighting that if a patient has a metastatic or advanced cellular tumor type and there is a genomic biomarker that is linked to a therapy approved for a regulatory agency, or they have a tumor type where there's a drug that's approved but there's a known genomic resistance marker, these are scenarios where we feel patients should get genomic testing. Now, the more complicated area, a little more controversial, has been scenarios where the patient has a disease that is not one of those diseases that has a disease-specific approval for a drug. And in that scenario, we believe there's still value in genomic testing for several reasons. There's been several new drug approvals for what we call tumor-agnostic drugs. That means if you have an alteration that gives you sensitivity to immunotherapy because you have what we call microsatellite instability, and some next-generation sequencing panels can report that out, then, regardless of your tumor type, you may be able to get offered immunotherapy. If you have multiple mutations in your tumor, something we call the increased tumor mutation burden, that is now linked to immunotherapy approval. So irrespective of tumor type, if a patient is eligible for immunotherapy, they benefit from getting genomic testing. And then on top of that, we now are seeing more and more that patients may have a genomic alteration that we think is a compelling target. But they may have it-- they may have it in a disease where that drug was not approved. And we're now starting to see that in many clinical trials. We're seeing activity by targeting those alterations. So there may be additional opportunities, especially for clinical trial enrollment, by identifying these potentially actionable alterations in other diseases. So taking this together, we believe multigene testing will provide both additional approved indications and clinical trial indications. And in addition, fusion testing can identify TRK fusions, a fusion type that's found commonly in some uncommon cancers and uncommonly in some common cancers. But when it's found, it is a very compelling target. So again, because patients would be eligible for TRK inhibitors, irrespective of their tumor type, that's another scenario where next-generation sequencing may be beneficial for patients with advanced and metastatic disease, irrespective of tumor type. Greg Guthrie: Wow, that's just an amazing overview right there. And one question that occurs to me is, is all of this genetic testing done from a biopsy sample? Or are there other ways a patient may experience this testing? Dr. Meric-Bernstam: The traditional tumor-based testing is usually done either from a surgical sample or a biopsy sample. And again, it could be tumor-only testing or tumor plus a normal. Usually, normal would be something like blood as a comparator. However, there are times where a patient doesn't have a tumor accessible for a biopsy. In that scenario, there is now the opportunity to look at circulating free DNA to do panel testing on circulating free DNA for some of the more common actionable alterations. So there's a lot of momentum in using that approach, and this is what we often refer to as a liquid biopsy. And the liquid biopsy strategy is also very interesting because it's another way to pick up what changes of the tumor with treatment as well. So there's a lot of research going into using liquid biopsies when the patient also progresses on targeted therapy to see what has changed and how we need to change our therapy to address the tumor's evolution. Greg Guthrie: Wow. Thanks for that, Dr. Meric-Bernstam. Dr. Robson, what are the emerging ways that genetic testing may be used to help people with cancer? Dr. Robson: I think there are many, many ways. I was reflecting on this question, and I think it's important to kind of separate, as we did earlier, what we mean by genetic testing, again, because I think there's a lot of confusion. And there's certainly a lot of work going on in terms of testing of inherited DNA, so germline testing, to identify risks for cancer and potentially therapeutic targets. And that's not something that was discussed in this particular opinion, but it is an important way that genetics is being used to help people. On the side of the folks who already have cancer, the application of genetic technologies, as Dr. Meric-Bernstam said earlier, is identifying more and more targets. In other words, more and more alterations that are driving the cancers and for which we can test new drugs and hopefully achieve successes in a much more focused and less toxic way. And that work is going on at an exponential pace, and indeed, perhaps most of the new drugs that are entering the development pathway right now are indeed targeted therapies, not conventional broad-spectrum chemotherapies. The genetic technologies are also being used as, again, Dr. Meric-Bernstam said, to look at DNA from the tumors that are circulating in the bloodstream. And one way is the liquid biopsy, which is for characterization. But another way that's coming online is just simply to look for the presence or absence of circulating DNA in people who are, for instance, post-op and don't have any evidence of disease to see whether or not they might, in fact, have some cancer that hasn't been detected by imaging. And then the hope is that we could then intervene earlier in that setting and perhaps prevent those circulating DNA from representing true metastasis, detectable metastasis. And again, a lot of work going on there. And there's a diagnostic and prognostic component to what's happening as well. There are, unfortunately, a number of people who present with metastatic cancer, and it's not obvious at all where that started. And work is being done now to use testing of the tumor DNA to help categorize the tumors, to direct the correct therapies, instead of just doing something generic and empiric. And there are many, many other ways that genetic technologies are being applied. It's really 1 of the 2 big frontiers in cancer therapy right now. The other one, of course, being immunotherapy. But it is an exciting time, and I think it's just going to continue to grow as the technologies become more and more innovative. Greg Guthrie: That's really exciting. And thank you for sharing all of that perspective. I really wonder if helping with this somatic testing can help increase enrollment in clinical trials, too, to advance progress in other rare cancers? Dr. Robson: I think it did, not necessarily just in rare cancers. I mean, people are— Greg Guthrie: Agreed. Dr. Robson: —certainly doing testing in common diseases and identifying these new targets. And you're exactly right. The only way we're going to be able to develop new therapies in that setting is through clinical trials. And so, for the appropriate people, genetic testing or testing of the tumor or somatic testing could very well identify clinical trial opportunities for them, and that's the way we're going to move forward. Greg Guthrie: Outstanding. And again, I really love this distinction between somatic and germline testing and clarifying that for our listeners today. Dr. Meric-Bernstam and Dr. Robson, thanks so much for your time today and for sharing your expertise on these ASCO recommendations. It's been great having you and chatting with you today. Dr. Robson: Thanks. Dr. Meric-Bernstam: Thank you for having us. Greg Guthrie: And for our listeners, if you'd like to learn more about genetics, genetic testing, and cancer, visit www.cancer.net/genetics. Thanks so much for joining us today, and be well. ASCO: If this podcast was useful, please take a minute to subscribe, rate, and review the show wherever you listen to podcasts. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping patients everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Mark Robson on buying Jared Payne lobster pots, being a hit in Guatemala and Twitter trolls by Belfast Telegraph Sport

This first episode is all about the shocking and sensual '40s classic, The Seventh Victim, produced by RKO maestro Val Lewton and directed by Mark Robson, who became famous for "Valley of the Dolls" a couple decades later.